『What Compounding Pharmacies Cannot Say About Safety & Effectiveness in Medicine – Darshan Kulkarni』のカバーアート

What Compounding Pharmacies Cannot Say About Safety & Effectiveness in Medicine – Darshan Kulkarni

What Compounding Pharmacies Cannot Say About Safety & Effectiveness in Medicine – Darshan Kulkarni

無料で聴く

ポッドキャストの詳細を見る
The personalized medicine and compounding pharmacy industry is evolving rapidly as patient demand, regulatory scrutiny, and technological innovation continue to collide. In this episode of Compounding Interest: The Business of Personalized Medicine, host Amy Summers sits down with Darshan Kulkarni to explore the legal and ethical challenges facing compounding pharmacies today. From FDA advertising rules and promotional claims to USP 797, 503A vs. 503B pharmacies, peptides, and the future of personalized medicine, this conversation examines where innovation meets regulation and where the industry's biggest gray areas remain.Darshan Kulkarni, PharmD, MS, Esq., is a pharmacist, attorney, educator, author, and founder of Kulkarni Law Firm, where he advises FDA-regulated industries on complex regulatory and compliance matters for the Life Sciences. His expertise spans pharmacy compounding, medical devices, advertising compliance, clinical research, and FDA law. His multidisciplinary background provides a unique perspective on balancing patient access, innovation, and regulatory responsibility.Key TakeawaysWhy patient safety, efficacy, affordability, and access must all be balanced in personalized medicine.The legal boundaries surrounding advertising and promotional claims for compounding pharmacies.How FDA regulations, USP 797, and 503A/503B distinctions impact pharmacy operations.The regulatory challenges surrounding peptides, compounded medications, and personalized therapies.Practical guidance for pharmacies navigating compliance while continuing to serve patients effectively.Timestamps[00:00:00] - Introduction to Darshan Kulkarni and Personalized Medicine: Amy introduces Darshan and discusses how his pharmacy and legal background shapes his perspective.[00:05:15] - The Purpose and Evolution of Pharmacy Compounding: A discussion on FDA oversight, drug shortages, the NECC tragedy, and the growth of modern compounding.[00:09:53] - Common Compliance Mistakes in FDA-Regulated Industries: Darshan explains the regulatory issues he sees most often across healthcare companies.[00:14:09] - Marketing Rules for Compounding Pharmacies: Which advertising claims pharmacies should avoid and how they can market responsibly.[00:21:59] - Why Disclaimers Cannot Replace Regulatory Compliance: Understanding the limits of disclaimers in pharmaceutical advertising.[00:26:01] - Peptides and the Ongoing Regulatory Debate: A discussion on safety, efficacy, patient access, and the legal concerns surrounding peptide products.[00:31:13] - Buying a Compounding Pharmacy: Darshan shares advice on finding acquisition opportunities through networking, brokers, and industry relationships.[00:32:55] - Closing Thoughts and Final Takeaways: Amy wraps up the conversation by reflecting on the importance of thoughtful debate in personalized medicine.Follow Darshan Kulkarni:LinkedIn: https://www.linkedin.com/in/darshankulkarni/Website (Company): https://kulkarnilawfirm.com/LinkedIn (Company): https://www.linkedin.com/company/kulkarnilaw/ X (Company): https://x.com/kulkarnilawfirmYouTube: www.youtube.com/@DarshanTalksFollow the Host:Amy Summers: https://www.linkedin.com/in/amy-summers-pharmd-bcscp-fapc-20b04a93/Restore Health Consulting: https://www.restorehealthconsulting.com/Follow The Podcast:YouTube: https://www.youtube.com/@RestoreHealthConsultingSpotify: https://open.spotify.com/show/033F4FRUbjSrN1oNbfozhD?si=caf30ccfd2ba49b6Apple Podcasts: https://podcasts.apple.com/in/podcast/compounding-interest/id6784679391
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません